 SAN DIEGO, Sept. 29, 2021 PRNewswire -- BioAtla, Inc. Nasdaq: BCAB, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic CAB antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock. 